TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06892522: A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Sponsor: AbbVie · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 602 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$6,990,060

Rescue Site Savings

+$4,594,590

Unlock Full NCT06892522 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06892522 Rescue Dossier →